Geriatrics

The DR market is expected to accrue a sum of $2,490 million by 2022, growing at a compound annual growth rate of 14.4% from 2014-2022.

Risk of scar development increased from three-fold at 2 years to 4.5-fold at 5 years, possibly as a result of treated quiescent classic lesions that relapsed over time.

How come treat-and-extend may not be the most ideal therapy regimen for retina disease, and how biologics change physicians' perspective on dosing.

Are anti-VEGF and PRP therapies the best-case scenario for patients with AMD, or will gene therapies reach the market in the near future?

How the three-year results of a gene therapy for inherited retinal disease may redefine its potential in ophthalmology.

A three-year update of VN for patients with biallelic RPE65 mutation-associated inherited retinal disease improved on the common standard-of-care for retina disease.

Results from the PACORES group clinical trial debunked previously-held beliefs that IVB is unsafe for patients with proliferative diabetic retinopathy undergoing the procedure.

Why substantial evidence is lacking to indicate either therapy method's preference for the treatment of neovascularization.

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

How improvements to patient education, drug costs, and biosimilar therapy availability could keep patients with retina disease away from risky procedures.

Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.

Researchers found testing is significantly more practiced by patients offered it in person, versus those referred, with little difference found in mutation identification.

Though cell therapies have gained FDA approval to treat any ocular disease, companies have marketed predominately to patients with AMD, with procedures that could lead to blindness.

Though the 2 dosing regimens had comparable visual acuity improvements over 24 months, patients given ranibizumab once-monthly received treatment nearly 6 more times on average.

Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.

The first meta-analysis of AMD clinical meta-analyses shows many have methodological limitations—more so those sponsored by industry than those sponsored by governments.

Emixustat has been shown in previous preclinical analysis to slow the visual cycle and inhibit the activity of RPE65 and associated loss of photoreceptors associated with RPE dysfunction.

To the knowledge of researchers, this is the first demonstration to show C3a can stimulate basal deposit production by normal human RPE cells.

Utilizing research from the Age-Related Eye Disease Study 2, researchers found that MA and GA may be part of the same disease process affecting the visual acuity of patients with AMD.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

With the approval, the syringe becomes the first with anti-VEGF agent approved by the FDA for use to treat DR and DME.

The anti-VEGF marketed as EYLEA has new phase 3 study results in its ongoing trial for NPDR consideration.

For treating AMD, the 3 anti-VEGF agents report similar efficacy and safety results in trials but different molecular structure and biochemical properties.

Brimonidine was previously approved by the FDA in 1996 for the treatment of intraocular pressure reduction in patients with glaucoma.